替考拉宁治疗G+菌感染的疗效和安全性

目的：评价替考拉宁治疗G^ 菌感染的疗效和安全性。方法：采用随机对照及开放试验，以万古霉素为对照。完成病例60例，其中试验组30例，替考拉宁0．2～0．4g，qd，静脉滴注；对照组30例，万古霉素0．5g，tid，静脉滴注。疗程均为7～14d。结果：试验组痊愈率、有效率、细菌清除率分别为50％，80％和83．3％，对照组分别为46．7％，76．7％和76．7％，2组差异无显著性。不良反应发生率分别为10％和13．3％，2组差异亦无显著性。结论：替考拉宁治疗G^ 菌感染安全有效。

Clinical evaluation of teicoplanin in treatment of gram-positive bacterial infections

Objective:To study the safety and efficacy of teicoplanin in treatment of gram-positive bacterial infections. Methods: In the randomized, controlled and opened clinical trial, 60 patients were equally divided to receive once daily dose of 0.2-0.4g teicoplanin given by infusion for 7-14d or 3 times daily dose of 0. 5g intravenous vancomycin for 7-14d. Results:The cure rate, total effective rate and bacterial clearance rate were 50 % , 80 % , and 83.3% respectively for teicoplanin group and were 46.7% ,76.7% and 76.7% respectively for control group. 10% adverse drug reactions occurred in teicoplanin group and 13.3% in vancomycin group.Conclusion:Teicoplanin seems to be a highly effective and safe agent for treatment of gram-positive bacterial infections.